Abstract: A photoinduced carrier lifetime measuring method capable of obtaining photoinduced carrier effective lifetime of a semiconductor substrate with high accuracy regardless of the surface state of the sample. The method includes: irradiating a microwave onto a semiconductor substrate while periodically pulse-irradiating a light onto the semiconductor substrate; detecting the microwave transmitted through the semiconductor substrate or reflected by the semiconductor substrate; and obtaining the effective lifetime of photoinduced carriers generated in the semiconductor substrate by the pulse irradiation of the light, based on an irradiation duration T1 and a non-irradiation duration T2 when performing the light pulse irradiation and an integrated value of each microwave intensity obtained by the detection.

Abstract: This invention provides for the design of novel nitrile oxidoreductases that can be used as biocatalysts for industrial chemical processes and; and thus, provide attractive alternatives to traditional chemical synthesis. Generally, this technology relates to crystal structures of nitrile oxidoreductases, and of crystal structures of nitrile oxidoreductases complexed with substrates and co-factors. For example, the invention provides for the crystalline structure of the nitrile oxidoreductase, QueF, as well as for a computer-readable medium having QueF crystal structure information stored thereon.

Abstract: The present inventors have solved the crystal structure of an Escherichia coli bacterial lipocalin polypeptide, which depicts a monomeric protein. Previous crystal structures have been reported, but these appear to be inaccurate, as they predicted, e.g., a dimeric protein. The crystal structure of a bacterial lipocalin provided by the present invention leads to numerous uses. For example, the present invention provides for the design, construction and use of recombinant libraries of diversified bacterial lipocalins resulting from a bacterial lipocalin polypeptide “backbone”.

Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.

Abstract: Protein A crystals and Protein A cross-linked protein crystals (CLPCs) are described. Methods of preparing and using are also disclosed.

Abstract: Embodiments of the present invention provide methods, microfluidic devices, and systems for the detection of an active target agent in a fluid sample. A substrate molecule is used that contains a sequence which may cleave in the presence of an active target agent. A SNAP25 sequence is described, for example, that may be cleaved in the presence of Botulinum Neurotoxin. The substrate molecule includes a reporter moiety. The substrate molecule is exposed to the sample, and resulting reaction products separated using electrophoretic separation. The elution time of the reporter moiety may be utilized to identify the presence or absence of the active target agent.

Abstract: A method for making a number (N) of samples react under the same reaction conditions that includes heating a number of reaction containers simultaneously and maintaining the reaction containers at a predetermined temperature; placing a sample in each heated reaction chamber and maintaining a two-phase solution at a predetermined temperature; stirring the sample that is heated to the predetermined temperature to create a uniform solution, which is maintained for a predetermined time; and cooling the uniform solution without cooling the reaction container after the predetermined period of time has passed so as to gain a two-phase solution within the reaction container, where the samples have a solution where the phase state of a reaction solvent changes in a reversible manner between a two-phase solution state and a uniform solution state when the temperature fluctuates over or under a certain constant temperature.

Abstract: Novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase.

Abstract: The present invention relates to a three-dimensional structure of the intracellular domain (AICD) of human amyloid precursor protein (APP695) in complex with human Fe65-PTB2 (i.e. a protein-complex comprising the intracellular domain (AICD) of human amyloid precursor protein (APP695) and the human Fe65-PTB2), as well as to methods and uses of said three-dimensional structure for identifying ligands which modify the interaction between the AICD and the Fe65-PTB2. Moreover, the present invention relates to pharmaceutical compositions which contain one or more of such identified ligands for the prevention or treatment of neurodegenerative disorders.

Abstract: The present invention includes a crystal comprising a complex of the pro form of a matrix metalloprotease (proMMP) and a small-molecule allosteric processing inhibitor that inhibits that activation of the proMMP, methods for identifying small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP, and methods of treatment using small-molecule allosteric processing inhibitors that inhibit the activation of a proMMP. The present invention relates to the crystal structure of a complex of proMMP9 bound to a small-molecule allosteric processing inhibitor that inhibits activation of proMMP9. The invention further relates to the use of the methods and the crystal and related structural information for designing, selecting and/or optimizing small-molecule allosteric processing inhibitors that inhibit activation of proMMP9 and proMMP9 homologues.

Abstract: A crystal comprising human isoglutaminyl cyclase having a characterized space group of P1211 and unit cell dimensions of +/?5% of a=126.51 ?, b=109.68 ?, c=159.53 ?, ?=90.0°, ?=104.9° and ?=90.0°.

Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.

Abstract: A nanovolume microcapillary crystallization system allows nanoliter-volume screening of crystallization conditions in a crystal card that allows crystals to either be removed for traditional cryoprotection or in situ X-ray diffraction studies on protein crystals that grow within. The system integrates formulation of crystallization cocktails with preparation of the crystallization experiments. The system allows the researcher to select either gradient screening in crystallization experiments for efficient exploration of crystallization phase space or a combination of sparse matrix with gradient screening to execute one comprehensive hybrid crystallization trial.

Abstract: This invention relates to methods for evaluating or inhibiting the aggregation of a protein in an aqueous suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution including sugar and a non-ionic surfactant.

Abstract: Methods and devices for assaying the effectiveness of a cleaning composition in removing a protein or a biofilm from a surface are disclosed. Such methods include the steps of providing one or more proteins at an interface between an aqueous phase and a liquid crystal phase or at the surface of a liquid crystal, contacting the interface or liquid crystal surface with a cleaning composition, and observing the orientational ordering of the liquid crystal at the interface or liquid crystal surface. A continuous change in the orientational ordering of the liquid crystal at the interface or liquid crystal surface indicates that the proteins are being removed from the interface, and the rate of change in orientational ordering, the extent of the change in orientational ordering, or both, are correlated with the effectiveness of the cleaning composition.

Abstract: The crystal structure of the ligand binding domain of ERR-? in complex with a ligand that forms a reversible thioether bond to Cys325 of ERR-?, methods to measure dissociation rates for ligands that form reversible covalent bonds, and methods to design ligands that form reversible covalent bonds for use as modulators of ERR-? activity are disclosed. The crystal structure and methods provide a novel molecular mechanism for modulation of the activity of ERR-? and provide the basis for rational drug design to obtain potent specific ligands for use as modulators of the activity of this new drug target.

Abstract: The invention relates to a crystal of the CC2-LZ domain of the NEMO protein, in which the three-dimensional structure has been determined by X-ray diffraction at a resolution of about 3.25 A. The invention also relates to methods for the crystallization of the CC2-LZ domain. The CC2-LZ crystals and the information derived from the crystalline structures thereof are used for identifying and designing compounds interacting with CC2-LZ.

Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.

Abstract: Fluid flow devices include a small plate (2), at least one flow channel (20) formed into this small plate, at least one storage channel (221-226) extending from this connection channel, and a set of valves (V1-V6), each of which is suitable for allowing or stopping the flow of fluid in a corresponding storage channel.

Abstract: A novel crystal structures of human and murine glutaminyl cyclase (QC, EC 2.3.2.5), methods of preparing the crystals, as well as the use of said crystal structures for identifying inhibitors of human and murine glutaminyl cyclase.

Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.

Abstract: The invention herein disclosed provides for compositions, methods for synthesizing said compositions, and methods for using said compositions, wherein the compositions and methods may be used to bind to and/or deactivate a poison oak oil, such as urushiol. The compositions and methods can be used to treat and/or reduce an inflammatory reaction and/or hypersensitivity to natural compounds found in poison oak, poison ivy, poison sumac, mango, lac tree, and cashew nut.

Abstract: The present invention provides a technique for crystallizing a desired protein at a high probability; namely, a protein crystallizing agent and a method of crystallizing protein. The present invention also provides a technique for determining the conditions for protein crystallization easily with high efficiency; namely, a method of screening the conditions for protein crystallization and a protein crystallization screening reagent. As the protein crystallizing agent, at least one compound selected from the group consisting of a basic amino acid, acidic amino acid, ester derivative of amino acid and amide derivative of amino acid is used, or at least one of these compounds is used in combination with another protein crystallizing agent.

Abstract: A crystal, a preparation method and 3D structure of CD147 extracellular region are provided. Such 3D structure is useful in the determination of the active site of CD147 extracellular region by computer modeling or molecular docking method. The crystal and/or 3D structure are useful in a structure-based drug design and the selection of an antibody, a ligand or an interacting molecule of CD 147 extracellular region.

Abstract: This invention relates to a novel, bacterial GTP Cyclohydrolase Type IB enzyme, and the crystal structure thereof.

Abstract: The present invention provides apo crystals and co-crystals of insulin-degrading enzyme (IDE) and their uses in drug development.

Abstract: The present disclosure provides a method to allow a user to pre-screen numerous crystallization conditions in the crystallization space to identify those conditions with the highest probability of yielding crystals and high quality diffracting crystals. In one embodiment, the dilute solution thermodynamic virial coefficient, termed B, is used to aid in the determination crystallization conditions that increase the probability of producing crystals for the crystallant of interest. The present disclosure also provide methods for predicting solution conditions that generate beneficial solubility and/or stability conditions for a polypeptide of interest using the B parameter. Devices for use in the described methods are also described.

Abstract: Described herein are substrates coated with crystals having uniform crystalline morphology on the surface of the substrate. The coated substrates are useful in culturing and performing functional assays on cells such as, for example, resorption studies on bone cells. New methods for producing such coated substrates are also disclosed.

Abstract: The crystal structure of the ligand binding domain of ERR-? in complex with a ligand that forms a reversible thioether bond to Cys325 of ERR-?, methods to measure dissociation rates for ligands that form reversible covalent bonds, and methods to design ligands that form reversible covalent bonds for use as modulators of ERR-? activity are disclosed. The crystal structure and methods provide a novel molecular mechanism for modulation of the activity of ERR-? and provide the basis for rational drug design to obtain potent specific ligands for use as modulators of the activity of this new drug target.

Abstract: The invention relates to batch crystallization methods for crystallizing an anti-hIL-12 antibody that allows the production of the antibody on an industrial scale, antibody crystals obtained according to the methods, compositions containing the crystals, and methods of using the crystals and the compositions.

Abstract: The present invention provides systems and methods for data acquisition and image analysis that utilize twisted nematic liquid crystals (“TNLCs”) to create maps of bio/chemical functionality patterned on surfaces. The method involves the acquisition of a series of images of TNLC film that contacts the analytic surface followed by analysis of the series of images to yield maps of twist angle of the liquid crystal across the surface. This analysis technique effectively condenses a large data set (stack of images) into a compact form (map of twist angle), revealing features on the surface that were not apparent in the individual images comprising the original stack.

Abstract: The present invention provides crystalline molecules or molecular complexes which comprise binding pockets of Aurora-2 or its homologues. The invention also provides crystals comprising Aurora-2. The present invention also relates to a computer comprising a data storage medium encoded with the structural coordinates of Aurora-2 binding pockets and methods of using a computer to evaluate the ability of a compound to bind to the molecule or molecular complex. This invention also provides methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention provides methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to Aurora-2 or homologues thereof.

Abstract: A human laminin receptor crystal is disclosed. Methods are disclosed for using various computer and non-computer means in order to develop models for use in the development of novel therapeutics that block and/or mimic laminin receptor interactions in the setting of, among others, Alzheimer's disease, other neurological disorders, cancer, and viral and bacterial infections.

Abstract: An integrated fluidic circuit includes a substrate layer and a first structure coupled to the substrate layer and including a plurality of channels. The first structure is configured to provide for flow of one or more materials through the plurality of channels. The integrated fluidic circuit also includes a second structure coupled to the substrate layer. The second structure includes a plurality of control channels configured to receive an actuation pressure. The integrated fluidic circuit is characterized by a thickness of less than 1.5 mm.

Abstract: This invention relates to a crystallizable composition comprising a TSHR polypeptide, to crystals comparing a TSHR polypeptide and to TSHR-related applications.

Abstract: The present disclosure provides a method to allow a user to pre-screen numerous crystallization conditions in the crystallization space to identify those conditions with the highest probability of yielding crystals and high quality diffracting crystals. In one embodiment, the dilute solution thermodynamic virial coefficient, termed B, is used to aid in the determination crystallization conditions that increase the probability of producing crystals for the crystallant of interest. The present disclosure also provide methods for predicting solution conditions that generate beneficial solubility and/or stability conditions for a polypeptide of interest using the B parameter. Devices for use in the described methods are also described.

Abstract: The present invention relates to Pregnane X receptor (PXR) polypeptides and crystals that are useful, for example, for crystallization and in assays for identification of modulators of PXR.

Abstract: The present invention relates to a batch crystallization method for crystallizing an anti-hTNFalpha antibody which allows the production of said antibody on an industrial scale; antibody crystals as obtained according to said method; compositions containing said crystals as well as methods of use of said crystals and compositions.

Abstract: Methods for detecting and evaluating the quality of protein crystals are provided comprising subjecting a sample to second order non-linear optical imaging and detecting the second harmonic generation signal.

Abstract: Test device for detection and visual indication of a specific analyte in a liquid sample such as a body fluid. The device includes a biodegradable housing, a test strip and a lid. The device is configured for placement in concentrate or dilute test liquid that is for example contained in a vessel. One end of the test strip wicks the liquid being tested into the housing and across a control site and test site which provide visual indication that the device is working correctly and whether the analyte being tested is present in the test liquid. An antibody specific to the antigen being tested may be provided on the test strip. The test device for example detects specific antigens in dilute urine, such that the device may be placed in a toilet bowl after urination.

Abstract: The present disclosure concerns methods of crystallization and/or concentration of antibody or antibody fragments. The methods comprise contacting an antibody or antibody fragment with a solution comprising a salt of a divalent cation. Crystals and/or protein gels of antibody or antibody fragments are useful in compositions and formulations.

Abstract: The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.

Abstract: A leak detection material and method of introducing the leak detection material into a fluid system such as a climate control system, an engine oil system, or a fuel system is described. The leak detection material can be a dye delivery composition including a mixture of leak detection dye and a solid carrier.

Abstract: The present invention concerns determination of the crystal structure of the macrophage specific receptor, CRIg (earlier referred to as STIgMA), and its complex with the C3b and C3c subunits of complement C3 (C3b:CRIg and C3c:CRIg complexes). The invention further concerns the use of the crystal structure of CRIg or the C3b:CRIg complex to screen for and identify molecules structurally and/or functionally related to CRIg, including CRIg agonists and antagonists.

Abstract: The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and an alcohol. Other aspects of the invention include related immunoassays and test kits.

Abstract: The compositions, methods and systems of the invention provide nanocrystal taggants for unobtrusive monitoring of objects. Objects can be tagged with nanocrystal taggant compositions for detection of informative invisible emissions on illumination with appropriate excitation wavelengths.

Abstract: The present invention provides microfabricated substrates and methods of conducting reactions within these substrates. The reactions occur in plugs transported in the flow of a carrier-fluid.

Abstract: This invention relates to crystals of whole antibodies and fragments thereof, and formulations and compositions comprising such crystals. More particularly, methods are provided for the crystallization of high concentrations of whole antibodies, and fragments thereof, in large batches, and for the preparation of stabilized whole antibody crystals for use alone, or in dry or slurry formulations or compositions. This invention also relates to methods for stabilization, storage and delivery of biologically active whole antibody crystals.

Abstract: The present invention discloses a modified tumor necrosis factor-alpha converting enzyme (TACE) catalytic domain, that unlike the native TACE catalytic domain, is stable at high protein concentrations. The present invention further discloses methods for generating crystals of the modified TACE protein in protein-ligand complexes with a number of inhibitors. In addition, the present invention discloses methods of using the proteins, crystals and/or three-dimensional structures obtained to identify compounds that can modulate the enzymatic activity of TACE.

Abstract: The present invention discloses nucleic acids that encode an active human Aurora 2 kinase catalytic domain. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active human Aurora 2 kinase catalytic domain. The present invention further discloses a crystalline form of a catalytic domain of human Aurora 2 kinase. In addition, the present invention discloses methods of using the X-ray diffractable crystals of human Aurora 2 kinase in structure assisted drug design to identify compounds that can modulate the enzymatic activity of human Aurora 2 kinase.